Orphan Drug Makers Get Selected Tax Breaks As China Turns To Access
Executive Summary
Following anticancer drugs, rare disease treatments become the latest products in China’s to get value added tax reductions. Orphan drug makers can breath easier, but much more is needed, industry insiders say.
You may also be interested in...
Rare But Real: How One Startup Is Willing Itself To Lift China Orphan Drug Market
As a promising market for orphan drugs, China has seen several approvals in this space in the past six months, mostly from multinationals. But Beijing-based CANbridge believes that a smaller biotech also has a good shot at a leadership role, despite a lack of funding and reimbursement and prickly pricing issues.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.